$ACAD
ACADIA PHARMACEUTICALS INC

2022 Q1 Form 10-Q Financial Statement

#000095017022007468 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $115.5M $106.6M
YoY Change 8.37% 18.3%
Cost Of Revenue $2.950M $2.185M
YoY Change 35.01% -56.3%
Gross Profit $112.5M $104.4M
YoY Change 7.81% 19.59%
Gross Profit Margin 97.45% 97.95%
Selling, General & Admin $96.68M $111.7M
YoY Change -13.42% 9.5%
% of Gross Profit 85.92% 106.99%
Research & Development $128.9M $56.97M
YoY Change 126.17% -21.56%
% of Gross Profit 114.52% 54.59%
Depreciation & Amortization $516.0K $525.0K
YoY Change -1.71% 78.57%
% of Gross Profit 0.46% 0.5%
Operating Expenses $225.5M $168.6M
YoY Change 33.74% -3.42%
Operating Profit -$113.0M -$66.77M
YoY Change 69.26% -25.41%
Interest Expense $105.0K $200.0K
YoY Change -47.5% -93.33%
% of Operating Profit
Other Income/Expense, Net $340.0K -$145.0K
YoY Change -334.48% -109.69%
Pretax Income -$112.6M -$66.43M
YoY Change 69.47% -24.51%
Income Tax $485.0K $21.00K
% Of Pretax Income
Net Earnings -$113.1M -$66.45M
YoY Change 70.14% -24.51%
Net Earnings / Revenue -97.91% -62.36%
Basic Earnings Per Share -$0.70 -$0.42
Diluted Earnings Per Share -$701.2K -$415.0K
COMMON SHARES
Basic Shares Outstanding 161.2M
Diluted Shares Outstanding 161.2M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $446.0M $577.8M
YoY Change -22.81% -11.3%
Cash & Equivalents $204.9M $304.5M
Short-Term Investments $241.1M $273.3M
Other Short-Term Assets $25.76M $28.50M
YoY Change -9.63% 28.96%
Inventory $13.21M $10.31M
Prepaid Expenses $25.76M
Receivables $62.71M $56.80M
Other Receivables $769.0K $600.0K
Total Short-Term Assets $542.2M $674.0M
YoY Change -19.55% -6.96%
LONG-TERM ASSETS
Property, Plant & Equipment $7.531M $72.90M
YoY Change -89.67% 432.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.336M $7.600M
YoY Change -42.95% 7.04%
Total Long-Term Assets $82.03M $81.20M
YoY Change 1.02% 251.52%
TOTAL ASSETS
Total Short-Term Assets $542.2M $674.0M
Total Long-Term Assets $82.03M $81.20M
Total Assets $624.3M $755.2M
YoY Change -17.34% 1.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.77M $8.800M
YoY Change 22.36% 33.33%
Accrued Expenses $108.8M $100.5M
YoY Change 8.27% 7.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $119.6M $109.4M
YoY Change 9.33% 9.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.373M $64.20M
YoY Change -93.19% 590.32%
Total Long-Term Liabilities $4.373M $64.20M
YoY Change -93.19% 590.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $119.6M $109.4M
Total Long-Term Liabilities $4.373M $64.20M
Total Liabilities $179.5M $173.6M
YoY Change 3.37% 59.12%
SHAREHOLDERS EQUITY
Retained Earnings -$2.267B
YoY Change
Common Stock $2.712B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $444.8M $581.6M
YoY Change
Total Liabilities & Shareholders Equity $624.3M $755.2M
YoY Change -17.34% 1.03%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$113.1M -$66.45M
YoY Change 70.14% -24.51%
Depreciation, Depletion And Amortization $516.0K $525.0K
YoY Change -1.71% 78.57%
Cash From Operating Activities -$76.33M -$60.15M
YoY Change 26.9% 22.75%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.076M
YoY Change -100.0% -215.7%
Acquisitions
YoY Change
Other Investing Activities $131.3M $31.95M
YoY Change 311.1% 4.62%
Cash From Investing Activities $131.3M $30.88M
YoY Change 325.38% 4.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.467M $7.726M
YoY Change -68.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.467M 7.726M
YoY Change -68.07% 105.81%
NET CHANGE
Cash From Operating Activities -76.33M -60.15M
Cash From Investing Activities 131.3M 30.88M
Cash From Financing Activities 2.467M 7.726M
Net Change In Cash 57.49M -21.54M
YoY Change -366.86% 37.75%
FREE CASH FLOW
Cash From Operating Activities -$76.33M -$60.15M
Capital Expenditures $0.00 $1.076M
Free Cash Flow -$76.33M -$61.23M
YoY Change 24.67% 27.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
000-50768
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC.
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147435000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
241057000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
373271000
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
06-1376651
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12830 El Camino Real, Suite 400
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
558-2871
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
ACAD
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161429360
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204920000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
62713000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
64366000
CY2022Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
769000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
978000
CY2022Q1 acad Short Term Inventory
ShortTermInventory
7009000
CY2021Q4 acad Short Term Inventory
ShortTermInventory
7881000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
25755000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23892000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
542223000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
617823000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7531000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8047000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58186000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58268000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q1 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6205000
CY2021Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6217000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4336000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3997000
CY2022Q1 us-gaap Assets
Assets
624251000
CY2021Q4 us-gaap Assets
Assets
700122000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
10768000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6876000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
108835000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
89192000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
119603000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
96068000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
55478000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
56126000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4373000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7034000
CY2022Q1 us-gaap Liabilities
Liabilities
179454000
CY2021Q4 us-gaap Liabilities
Liabilities
159228000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161381813
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161381813
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161012695
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161012695
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2712025000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2694646000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2266632000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2153576000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-612000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-192000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
444797000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
540894000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
624251000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
700122000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115468000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
106554000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115468000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
106554000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2950000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2185000
CY2022Q1 acad License Fees And Royalty Expense
LicenseFeesAndRoyaltyExpense
0
CY2021Q1 acad License Fees And Royalty Expense
LicenseFeesAndRoyaltyExpense
2507000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
128855000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56973000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
96679000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111661000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
228484000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
173326000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-113016000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-66772000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
105000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
200000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
340000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-145000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112571000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66427000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
485000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-113056000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-66448000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
161231000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
160011000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-113056000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-66448000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-422000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113476000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66450000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-113056000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-66448000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14963000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13184000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-447000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-689000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
339000
CY2021Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
145000
CY2022Q1 us-gaap Depreciation
Depreciation
516000
CY2021Q1 us-gaap Depreciation
Depreciation
525000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1653000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8585000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-209000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-1477000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-833000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
492000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1863000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2821000
CY2022Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1522000
CY2021Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1589000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3892000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
356000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
19672000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2761000
CY2022Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2117000
CY2021Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1052000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2661000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1567000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76329000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60149000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
127864000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
131345000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
159817000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1076000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
131345000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30877000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2467000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7726000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2467000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7726000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
57485000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21541000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153205000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210690000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
310257000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2021Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
45000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
540894000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
627009000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
444797000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
581606000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147435000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204920000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
326028000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
304487000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153205000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210690000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331798000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
310257000
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1728000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1114000
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5281000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6767000
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6205000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6217000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17540000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20297000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14963000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13184000
CY2022Q1 us-gaap Inventory Net
InventoryNet
13214000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14098000
CY2022Q1 acad Short Term Inventory
ShortTermInventory
7009000
CY2021Q4 acad Short Term Inventory
ShortTermInventory
7881000
CY2022Q1 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6205000
CY2021Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
6217000
CY2022Q1 us-gaap Inventory Net
InventoryNet
13214000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14098000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
727000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
108835000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
89192000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
213000
CY2022Q1 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
31497000
CY2021Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
15717000
CY2022Q1 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
29918000
CY2021Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
27270000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21645000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25896000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8944000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8304000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8641000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9319000
CY2022Q1 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
7021000
CY2021Q4 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
1959000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1169000
CY2022Q1 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
241683000
CY2022Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
0
CY2022Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
626000
CY2022Q1 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
241057000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
373475000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
9000
CY2021Q4 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
373271000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
32
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
39
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
238683000
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
626000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
238683000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
626000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
290997000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
213000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
290997000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
213000
CY2022Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
438512000
CY2022Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1497000
CY2021Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
499785000
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
603000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
603000
CY2022Q1 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Recorded
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseRecorded
873000
CY2022Q1 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Forfeited
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseForfeited
-30000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
51000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1497000
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
15100000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
4400000
CY2022Q1 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
13900000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
5500000
CY2022Q1 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Recorded
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseRecorded
900000
CY2022Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 1.8 years to 9.2 years, some of which include options to extend for up to two five-year terms.
CY2022Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
some of which include options to extend for up to two five-year terms.
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2110000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2378000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2190000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1014000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1440000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17417000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8944000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8304000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
55478000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
56126000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
64422000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
64430000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6869000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9338000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8327000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8407000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7771000
CY2022Q1 acad Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
36563000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
77275000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12853000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
64422000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.043
CY2020Q3 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
40300000
CY2020Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
40300000
CY2022Q1 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
19200000
CY2022Q1 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
19200000

Files In Submission

Name View Source Status
0000950170-22-007468-index-headers.html Edgar Link pending
0000950170-22-007468-index.html Edgar Link pending
0000950170-22-007468.txt Edgar Link pending
0000950170-22-007468-xbrl.zip Edgar Link pending
acad-20220331.htm Edgar Link pending
acad-20220331.xsd Edgar Link pending
acad-20220331_cal.xml Edgar Link unprocessable
acad-20220331_def.xml Edgar Link unprocessable
acad-20220331_htm.xml Edgar Link completed
acad-20220331_lab.xml Edgar Link unprocessable
acad-20220331_pre.xml Edgar Link unprocessable
acad-ex31_1.htm Edgar Link pending
acad-ex31_2.htm Edgar Link pending
acad-ex32_1.htm Edgar Link pending
acad-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending